Laurus Labs Invests in Laurus Bio, Increases Stake to 75.61%
Filing Summary
Laurus Labs Ltd has made an additional investment in its subsidiary, Laurus Bio Private Limited. The company acquired 13,487 Series A3 Compulsorily Convertible Preference Shares at a total cost of INR 35 Crores. This transaction was executed through a Private Placement cum Preferential Allotment. As a result, Laurus Labs now holds a 75.61% stake in Laurus Bio on a fully diluted basis. This update follows a prior communication dated December 6, 2024, regarding the investment in Laurus Bio.
On December 23, 2025, Laurus Labs Ltd announced an additional investment in its subsidiary, Laurus Bio Private Limited. The company acquired 13,487 Series A3 Compulsorily Convertible Preference Shares. The shares were purchased at a face value of INR 100 each, with a premium of INR 25,850.02 per share. The total investment amounted to INR 34,99,87,920, executed through a Private Placement cum Preferential Allotment.
This transaction increases Laurus Labs’ shareholding in Laurus Bio to 75.61% on a fully diluted basis. The investment was made under Regulation 30(7) of the SEBI (LODR) Regulations, 2015. This update follows a previous intimation dated December 6, 2024, regarding the company’s investment activities in Laurus Bio.
Laurus Labs Ltd focuses on the development and manufacturing of active pharmaceutical ingredients, generic formulations, and biotechnology products. The company prioritizes expanding its portfolio and enhancing its manufacturing capabilities to meet global pharmaceutical demands.